Fibroproliferative lung disease is prevalent and associated with high mortality. The
pathogenesis of fibrotic lung disease involves inflammation, mesenchymal cell proliferation …

Medical therapy for idiopathic fibrosis remains controversial. Idiopathic pulmonary fibrosis
(IPF) was uniformly a disease that progressed inexorably, typically leading to death within 3 …

During the past decade, significant advances have been made in the clinical understanding
of diffuse fibrotic lung disease. There now is a standardized diagnostic algorithm for …

Idiopathic pulmonary “brosis (IPF) is the most frequent idiopathic interstitial pneumonia with
a prevalence ranging from 5 to 15 per 100,000 persons, and above 175 per 100,000 in the …

Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with an
unfavorable outcome from progressively deteriorating respiratory function, leading ultimately …

After 50 years of clinical investigation, the role of corticosteroids in the treatment of idiopathic
pulmonary fibrosis remains unclear (1). One conclusion, however, is unavoidable …

Idiopathic pulmonary fibrosis (IPF) is a devastating illness for which current therapy is
minimally effective. If medical therapy for IPF is going to improve over the next decade …

There was a general consensus at the workshop that pulmonary fibrosis is a highly lethal
lung disorder and that current therapies for this disease have little effect on the natural …

Reprint requests: Dr Winterbauer, 1100 Ninth Ave, Seattle, WA 98101 great a risk for the
benefit obtained. Although age at onset, duration of disease prior to diagnosis, and rate of …

Why are corticosteroids used in patients with IPF? There is evidence that corticosteroid
therapy is associated with clinical improvement in only a small percentage of IPF patients …